(HER-2) has been utilized as a targeting site for the Trastuzumab drug delivery system. Trastuzumab is a humanized monoclonal antibody and has been widely used for HER2-positive metastatic breast cancer. [2] In the case of triplenegative breast cancer, [3] which is lacking the expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER-2/neu), other targeting mechanism are sought after. Interestingly, an overexpression of fructose transporter GLUT5 could be observed in cell lines such as MCF-7 and MDA-MB-231. [4] Glucose transporters (GLUTs) are transmembrane proteins, which participate in the cellular uptake of carbohydrates in order to provide energy for cellular metabolism. [5] This possible targeting mechanism has been investigated by Zhang et al. who have successfully applied fructose pendants on phosphorescent metal complexes to increase the cellular uptakes of the complexes. [6] The ruthenium complex-dichlororuthenium (II) (p-cymene) (1,3,5-triaza-7-phosphaadamantane) (RAPTA-C)-has shown to be remarkably effective at suppressing the growth of solid tumor metastases. However, poor delivery efficacy and the lack of targeting ability of the common drug delivery system pose significant obstacles to maximize the therapeutic benefit of RAPTA-C. Inspired by the overexpression of GLUT5 transporter on the surface of breast cancer tissues but not the healthy mammary tissues, the use of d-fructose as the targeting moiety of the drug carrier can significantly improve the cellular uptake of nanoparticles, thus further enhancing the therapeutic efficiency of RAPTA-C. In this work, fructose-micelles and 2-hydroxyethyl acrylate (HEA)-micelles are prepared to investigate the difference in cellular uptake. It is found that glycopolymer leads to an increased uptake by breast cancer cells, while the HEA-micelles show less uptake. This behavior is also reflected by the slightly faster movement of fructose-coated micelles in MCF-7 tumor spheroid models using light sheet microscopy as analytical tool. The incorporation of RAPTA-C into micelles can enhance the inhibitory effect of the ruthenium drug demonstrated using invasion, chemotaxis, and haptotaxis assays. As a result, fructose-coated nanoparticles can be a promising drug delivery platform of RAPTA-C for the treatment of metastatic breast cancer.